Who is YOUR NET Hero?

Honor your NET provider today!

Everyone deserves recognition and appreciation for doing their job well, and that certainly includes all the amazing NET health care providers. In honor of Doctors' Day 2022, we invite you to celebrate the commitment and care of your NET hero.

Now through April 30th, join us in showing your support and appreciation to your health care hero. You can make an online gift in honor of a health care provider who has made a difference in your life. Your donation will go toward funding essential research of improved treatments for neuroendocrine cancer. We’ll notify your provider about your thoughtful donation with a letter of gratitude and a Certificate of Applause. Click here to donate today!

An Everlasting Tribute to an Exceptional Young Man

Brandon Raabe lost his battle with neuroendocrine cancer just a few months shy of his 30th birthday. Since his passing, his friends and family have raised nearly $50,000 for NETRF in a little over one year's time. Read more about their remarkable fundraising efforts here.

Know Your NETs Patient Education Conference

What do YOU want to learn about NETs?

We are busy planning our 2022 Know Your NETs Virtual Patient Education Conference for July 24th, and we want to know what topics you'd like to learn more about. Please take 5 minutes to fill out the survey linked below to share your ideas for the agenda. We will keep the survey open until April 15, 2022 and we greatly appreciate your participation!

Take Survey Here

Have you listened to NETWise’s Focus on Liver NETs?

The latest episode of NETRF’s NETWise podcast is all about neuroendocrine tumors in the liver—the most common site of NET metastasis. You’ll hear physicians discuss the challenges of managing liver tumors and current treatment options, as well as patients who share their experience and perspective. Listen to this episode here.

Test Your Knowledge

After you've listened to the podcast, test your knowledge! Take the NETWise Quiz from LACNETS about Liver NETs.

What's Next for PRRT?

It’s been four years since peptide receptor radionuclide therapy (PRRT) was approved for NET patients in the United States. In the time since, physicians and scientists have been studying ways to expand the group of patients for whom this treatment may be appropriate and effective. In this presentation from NETRF’s 2021 KNOW YOUR NETs Patient Conference, Dr. Erik Mittra discusses “Future Advancements in PRRT.” Dr. Mittra is a professor of Diagnostic Radiology and Chief of Nuclear Medicine & Molecular Imaging at Oregon Health & Science University. Watch here.

First World NET Forum featured NETRF-funded Researchers

The European Neuroendocrine Tumor Society (ENETS) held its 19th Annual Conference earlier this month in Barcelona, Spain. The meeting brings together physicians and researchers from throughout the world to discuss the latest research on neuroendocrine cancer. More than 1500 participants attended in person or virtually. This year the meeting included the first World NET Forum, focusing on basic and translational science. NETRF was proud to sponsor the prizes for best abstracts. Read more here.

2021 NETRF Research Symposium Videos Online

The complete 2021 NETRF Research Symposium program is available for viewing on our website here. Individual session videos are available as well as the symposium poster series.

The 2021 symposium included nearly 60 presentations by NET researchers from around the world. Oral presentations were divided by the specific type of NET, resulting in four sessions, each hosted by two moderators with talks covering basic, translational, and clinical research projects. Each of the 27 talks was followed by a Q&A period, and each session ended with a panel discussion with session speakers, Co-Chairs, and the online audience.

Special thanks to Advanced Accelerator Applications for sponsoring this March E-update.

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

31 St. James Avenue, Suite 365
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.